Susanna Longo

Dr. Susanna Longo

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2023 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
Susanna LongoSusanna Longo
Susanna Longo
JLJacopo M. Legramante
Jacopo M. Legramante
SRStefano Rizza
Stefano Rizza
MFMassimo Federici
Massimo Federici

Verified
Journal Article
Open access
PDF file
MBMartina Belli
Martina Belli
LBLucy Barone
Lucy Barone
Susanna LongoSusanna Longo
Susanna Longo
FPFrancesca Romana Prandi
Francesca Romana Prandi
DLDalgisio Lecis
Dalgisio Lecis
FBFrancesco Barillà
Francesco Barillà
A great deal of evidence has revealed an important link between gut microbiota and the heart. In particular, the gut microbiota plays a key role in the onset of cardiovascular (CV) disease, including heart failure (HF). In HF, splanchnic hypoperfusion causes intestinal ischemia resulting in the translocation of bacteria and their metabolites into the blood circulation. Among these metabolites, the most important is Trimethylamine N-Oxide (TMAO), which is responsible, through various mechanisms, for pathological processes in different organs and tissues. In this review, we summarise the complex interaction between gut microbiota and CV disease, particularly with respect to HF, and the possible strategies for influencing its composition and function. Finally, we highlight the potential role of TMAO as a novel prognostic marker and a new therapeutic target for HF.

23 November 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
DLDalgisio Lecis
Dalgisio Lecis
FPFrancesca Romana Prandi
Francesca Romana Prandi
LBLucy Barone
Lucy Barone
MBMartina Belli
Martina Belli
DSDomenico Sergi
Domenico Sergi
FBFrancesco Barillà
Francesco Barillà
Atherosclerosis is a chronic inflammatory disease characterized by lipid and inflammatory cell deposits in the inner layer of large- and medium-sized elastic and muscular arteries. Diabetes mellitus (DM) significantly increases the risk of cardiovascular diseases and the overall and cardiovascular mortality, and it is a pro-atherogenic factor that induces atherosclerosis development and/or accelerates its progression through a multifactorial process. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a new class of drugs, belonging to the armamentarium to fight type 2 DM, that have shown robust reductions in atherosclerotic events and all-cause mortality in all studies. Preclinical studies have shown that GLP-1RAs play a role in the immunomodulation of atherosclerosis, affecting multiple pathways involved in plaque development and progression. In this review, we wanted to explore the translational power of such preclinical studies by analyzing the most recent clinical trials investigating the atheroprotective effect of GLP-1RAs.

30 June 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
MBMartina Belli
Martina Belli
LBLucy Barone
Lucy Barone
Susanna LongoSusanna Longo
Susanna Longo
FPFrancesca Romana Prandi
Francesca Romana Prandi
DLDalgisio Lecis
Dalgisio Lecis
FBFrancesco Barillà
Francesco Barillà
Much evidence reveals an important link between gut microbiota and the heart. In particular, the gut microbiota plays a key role in the onset of cardiovascular (CV) disease, including heart failure (HF). In HF, splanchnic hypoperfusion causes intestinal ischemia resulting in the translocation of bacteria and their metabolites into the blood circulation. Among these, the most important is the Trimethylamine N-Oxide (TMAO), which is responsible through various mechanisms for pathological processes in different organs and tissues. In this review, we summarise the complex interaction between gut microbiota and CV disease, particularly with HF, and the possible strategies to influence its composition and function. Finally, we highlight the potential role of TMAO as a novel prognostic marker and new therapeutic target of HF.

14 November 2025 in Pharmacological Research
Verified
Journal Article
Open access
Susanna LongoSusanna Longo
Susanna Longo
RMRocco Mollace
Rocco Mollace
VCViviana Casagrande
Viviana Casagrande
LBLoredana Bucciarelli
Loredana Bucciarelli
EMEugenio Martelli
Eugenio Martelli
MFMassimo Federici
Massimo Federici
Heart Failure with preserved Ejection Fraction (HFpEF) is a complex condition that stems from intricate biochemical changes in the heart tissue. The loss of metabolic flexibility, a hallmark of unhealthy myocardium, may play a role in its progression. However, the impact of myocardial metabolic changes on the development of HFpEF and the relationship with its diverse clinical presentations remains unclear. The heterogeneous nature of HFpEF poses a challenge to research and management, highlighting the pressing need for a deeper understanding of its pathophysiology and more accurate differentiation of its phenotypes. Multi-omics, driven by artificial intelligence and machine learning, is a source of inspiration in the field of HFpEF research. This method has the potential to reveal insights into the metabolic changes and phenotypes of HFpEF that were previously inaccessible. By revealing non-traditional biomarkers that go beyond basic clinical and demographic criteria, it also inspires the development of targeted therapies for specific patient groups. This review aims to explore the current understanding of how myocardial metabolic changes and metabolic inflexibility contribute to the pathogenesis of HFpEF. By drawing on the latest multi-omics studies, it also aims to identify an omics signature for HFpEF that could be instrumental in unearthing new biomarkers for diagnosis, phenotyping, risk stratification, and the development of tailored therapies, thereby advancing personalized medicine in the field of HFpEF.

24 January 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
Susanna LongoSusanna Longo
Susanna Longo
FCFederica Del Chierico
Federica Del Chierico
MSMatteo Scanu
Matteo Scanu
FTFrancesca Toto
Francesca Toto
JLJacopo Maria Legramante
Jacopo Maria Legramante
MFMassimo Federici
Massimo Federici
Background: The pathogenesis of many syncopal episodes remains unexplained. Intestinal dysbiosis could be involved in the pathophysiological mechanisms of syncope due to its connection with the central nervous system via the microbiota–gut–brain axis. This pilot study aimed to explore the specific cardiometabolic risk factors and gut microbiota in unexplained syncope (US), compared to other types of syncope, to assess their similarity or verify their different origins. Methods: We studied 86 participants with syncope, who were divided into four groups: an orthostatic syncope group (OH, n = 24), a neuromediated syncope group (NMS, n = 26), a cardiological syncope group (CS, n = 9), and an unexplained syncope group (US, n = 27). We evaluated the anthropometric, clinical, and metabolic characteristics of the four groups; the α- and β-diversity; and the differences in the abundance of the microbial taxa. Results: The US group had a lower incidence of systolic hypertension at the first visit and a lower frequency of patients with nocturnal hypertension than the CS group. Compared to the OH and NMS groups, the US group had a higher incidence of carotid plaques and greater carotid intima–media thickness, respectively. The microbiota differed significantly between the US and CS groups, but not between the US group and the OH or NMS group. Conclusions: We observed significant differences in the gut microbiota between CS and US. Future studies are necessary to evaluate the involvement of the gut microbiota in the complex pathogenesis of syncope and whether its analysis could support the interpretation of the pathophysiological mechasnisms underlying some episodes classifiable as US.